SELLAS Life Sciences to Present at the 30th Annual ROTH Conference

NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., SLS (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the 30^th Annual ROTH Conference on Monday, March 12, 2018 at 9:00 a.m. PT in Orange County, CA.

A live audio webcast of the presentation will be available under "Events & Presentations" in the Investors section of SELLAS' website at www.sellaslifesciences.com/investors.  A replay of the webcast will be available for up to 30 days on SELLAS' website following the presentation. 

About SELLAS Life Sciences Group

SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.  GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications.  SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesotheliomia (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer.  SELLAS plans to study GPS in up to four additional indications.  SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Investor Contact:

Will O'Connor

Stern Investor Relations, Inc.

212-362-1200

ir@sellaslife.com

David Moser, JD

SELLAS Life Sciences Group, Inc.

813-864-2571

info@sellaslife.com

Source: SELLAS Life Sciences Group, Inc.